SBIR-STTR Award

This Sbir Phase Ii Project Seeks To Continue Development Of A Low-Cost Home Visio
Award last edited on: 9/3/13

Sponsored Program
SBIR
Awarding Agency
NIH : NEI
Total Award Amount
$1,263,594
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Michael B Bartlett

Company Information

Vital Art And Science Inc

2725 North Spring Drive
Richardson, TX 75082
   (214) 929-2931
   info@myvisiontrack.com
   www.myvisiontrack.com
Location: Single
Congr. District: 03
County: Collin

Phase I

Contract Number: 1R43EY020016-01
Start Date: 9/30/09    Completed: 9/29/10
Phase I year
2009
Phase I Amount
$277,835
In the past decade effective therapies have been developed for diabetic retinopathy (DR), but all too many diabetics who are at high risk for developing the more advanced stages of diabetic retinopathy fail to get even the annual eye exams recommended by AAO, ADA and AMA, and many suffer preventable vision loss as a result. A major objective of RFA-EY-09-001 -- Innovative Patient Outreach Programs and Ocular Screening Technologies to Improve Detection of Diabetic Retinopathy -- is to "develop tools and systems to be used for increasing patient access to eye exams for detecting DR." Vital Art and Science Incorporated (VAS) was founded by a multi- disciplinary group of researchers and business people to specifically address this gap by creating a tool that can be put in the hands of the patient. The VAS goals are to validate and then commercialize a sub-$100 home vision self-test device that healthcare providers could supply to their patients for much more frequent and convenient screening to detect critical diabetic retinopathy state changes. This Phase I SBIR project is a "test of concept" for the prototype vision self-test device that VAS has developed for use in the home to track eye-disease progression. The goals are to assess the ability and willingness of diabetic patients to effectively use this device, as well as its efficacy in identifying when immediate care is needed. We will enroll 40 patients, who have already been diagnosed with diabetic retinopathy, in an 8- month clinical protocol requiring weekly self-testing with our prototype system at home, and scheduled in-office full vision exams (baseline, 4 months, 8 months) that include functional vision testing and retinal imaging analysis. The clinical results will be compared with the self-testing results in order to test the following hypotheses: 1) Patients are willing and able to perform vision self-test at home on a weekly basis. 2) The patients' self-test results strongly correlate with doctor's assessment of the progression of their retinopathy. Successful completion of this Phase I project will lead to a Phase II proposal in which we will develop the production version of our self-test system and perform additional cross-sectional and longitudinal trials to further verify efficacy of the self-test system, and to set specific guidelines for use by practitioners providing our self-test solution to their patients.

Public Health Relevance:
Over 5 million people in the US today suffer from diabetic retinopathy. A large number of those are at high risk for further vision loss, even though effective treatments exist, because they fail to receive timely eye exams, and subsequently, do not get treatment when it is needed. This SBIR project seeks to develop a low-cost home vision self-test system which enables diabetes patients to identify significant vision changes and to get treatment when it can be most effective to prevent vision loss.

Public Health Relevance Statement:
Narrative Over 5 million people in the US today suffer from diabetic retinopathy. A large number of those are at high risk for further vision loss, even though effective treatments exist, because they fail to receive timely eye exams, and subsequently, do not get treatment when it is needed. This SBIR project seeks to develop a low-cost home vision self-test system which enables diabetes patients to identify significant vision changes and to get treatment when it can be most effective to prevent vision loss.

Project Terms:
Address; Arts; Blindness; Businesses; Caring; Clinical; Clinical Protocols; Cognitive Discrimination; Detection; Devices; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Discrimination; Discrimination (Psychology); Disease; Disease Progression; Disorder; Electronics; Enrollment; Eye Exam; Eye Examination; Eye diseases; Goals; Grant; Guidelines; Hand; Health Care Providers; Health Personnel; Healthcare Providers; Healthcare worker; Home; Home environment; Human; Human, General; Image Analyses; Image Analysis; Investigators; Lead; Man (Taxonomy); Man, Modern; Marketing; Ophthalmic examination and evaluation; Output; Patients; Pb element; Phase; Physicians; Production; Protocol; Protocols documentation; ROC Analysis; Research Personnel; Researchers; Retinal; Retinal Diseases; Retinal Disorder; Running; SBIR; SBIRS (R43/44); SCHED; Schedule; Science; Screening procedure; Self Efficacy; Shapes; Sight; Small Business Innovation Research; Small Business Innovation Research Grant; Solutions; Staging; System; System, LOINC Axis 4; Technology; Test Result; Testing; Vision; Vision Tests; base; cost; design; designing; diabetes; diabetic; diabetic patient; disease/disorder; effective therapy; enroll; eye disorder; health care personnel; health care worker; health provider; healthcare personnel; heavy metal Pb; heavy metal lead; high risk; image evaluation; improved; innovate; innovation; innovative; medical personnel; ophthalmopathy; outreach program; prevent; preventing; prototype; public health relevance; retina disease; retina disorder; retinopathy; screening; screenings; tool; treatment provider; trend; willingness

Phase II

Contract Number: 2R44EY020016-02
Start Date: 9/30/09    Completed: 8/31/13
Phase II year
2011
(last award dollars: 2012)
Phase II Amount
$985,759

In the past decade, a number of new and effective therapies have been developed for the treatment of diabetic retinopathy (DR). Such therapies are only effective if administered prior to irreversible retinal damage which can occur if diabetics who are at high risk for developing the more advanced stages of diabetic retinopathy fail to get even the annual eye exams recommended by AAO, ADA and AMA.. Vital Art and Science Incorporated (VAS) was founded by a multi-disciplinary group of researchers and business people to specifically address this problem by creating a low cost and easy to use diagnostic tool which enables the patient to conveniently monitor their own DR progression at home and seek medical intervention at the earliest signs of visual loss. The VAS goals are to clinically validate and then commercialize a sub-$100 home vision function monitor that healthcare providers could prescribe to their diabetic patients for much more frequent screening to help detect critical changes in the retina so they can be examined and treated at the earliest possible time to maximize the effectiveness of therapeutic intervention and minimize preventable loss of vision. This project is a continuation of our Phase I where a first generation vision function test was developed and successfully tested in a 40 DR/DME patient, 6 month Study verifying that patients could and would effectively use our home vision monitor. This Phase II project is to enable VAS to further enhance the product based upon our Phase I Study feedback, perform a second usability test at the Cleveland Eye Clinic, and collaborate with a major pharmaceutical company to validate clinical sensitivity and specificity in an 80 DR/DME patient, 12 month Study. Successful completion of this Phase II project will directly lead to commercialization of the product for use in ophthalmic drug trials enabling pharmaceutical companies to collect significantly more data on new retinal compounds at a much lower cost than is currently possible. Such close collaboration with pharmaceutical companies is a crucial next step in the realization of our objective to provide a validated home based diagnostic for physicians to prescribe to their diabetic patients for monitoring and early detection of significant vision changes to maximize the effectiveness of therapeutic intervention and minimize preventable loss of vision.

Public Health Relevance:
Over 5 million people in the US today suffer from diabetic retinopathy. A large number of these patients are at high risk for vision loss, even though effective treatments exist, because they fail to receive timely eye exams, and subsequently, do not get medical treatment when it is most effective. This SBIR project seeks to develop a low-cost home vision function monitor which allows physicians to more frequently monitor their diabetic patients by enabling patients to perform their own vision test at home to identify significant vision changes and to get treatment when it can be most effective to prevent vision loss.

Thesaurus Terms:
Address;After Care;After-Treatment;Aftercare;Arts;Au Element;Blindness;Businesses;Clinic;Clinical Sensitivity;Collaborations;Data;Development;Diabetic Retinopathy;Diagnostic;Disciform Macular Degeneration;Disciform Senile Macular Retinal Degeneration;Disease;Disorder;Early Diagnosis;Effectiveness;Exudative Amd;Exudative Age-Related Macular Degeneration;Eye;Eye Exam;Eye Examination;Eyeball;Feedback;Generations;Goals;Gold;Health Care Providers;Health Personnel;Healthcare Providers;Healthcare Worker;Home;Home Environment;Intervention;Intervention Strategies;Investigators;Loinc Axis 4 System;Lead;Marketing;Measures;Medical;Monitor;Neovascular Amd;Neovascular Age-Related Macular Degeneration;Ophthalmic Examination And Evaluation;Patient Monitoring;Patients;Pb Element;Pharmaceutical Agent;Pharmaceuticals;Pharmacologic Substance;Pharmacological Substance;Phase;Phase I Study;Physicians;Research;Research Personnel;Researchers;Retina;Retinal;Sbir;Sbirs (R43/44);Science;Screening Procedure;Sensitivity And Specificity;Sight;Small Business Innovation Research;Small Business Innovation Research Grant;Staging;System;Testing;Therapeutic Intervention;Time;Vision;Vision Tests;Wet Amd;Base;Commercialization;Cost;Damage To Retina;Developmental;Diabetic;Diabetic Patient;Disease/Disorder;Early Detection;Effective Therapy;Effective Treatment;Function Improvement;Functional Improvement;Health Care Personnel;Health Care Worker;Health Provider;Healthcare Personnel;Heavy Metal Pb;Heavy Metal Lead;High Risk;Improved;Intervention Therapy;Interventional Strategy;Medical Personnel;Ophthalmic Drug;Phase 1 Study;Post Treatment;Prevent;Preventing;Retinal Damage;Screening;Screenings;Tool;Treatment Provider;Usability;Vision Loss;Visual Function;Visual Loss;Wet Form Of Amd